Landmark Bio has secured up to $18.3 million in funding from ARPA-H through its TRANSFORM-EV programme, with support from national advisory firm EverGlade. The three-year award will fund development of a continuous manufacturing platform for extracellular vesicles, potentially benefiting advanced therapies including viral vectors and cell therapies. The project aims to overcome current low-yield, high-cost batch manufacturing methods by integrating advanced upstream, downstream and analytical technologies. EverGlade supported Landmark Bio through negotiations, including multiple redesigns of work statements, milestones and financial documentation. EverGlade specialises in helping innovators navigate federal funding from agencies including ARPA-H, BARDA and DARPA. Landmark Bio, an Artis BioSolutions company, operates from Watertown, Massachusetts, providing process development and GMP manufacturing for advanced therapies.

Artis BioSolutions has appointed Dr Kate Broderick as Chief Scientific Innovation Officer, effective 9 February 2026. She will lead scientific strategy and innovation initiatives across the company's platform for developing and manufacturing genetic medicines. Dr Broderick brings over 25 years of experience in nucleic acid medicine and DNA- and RNA-based vaccine development. Most recently, she served as Chief Innovation Officer at Maravai LifeSciences. Previously, at Inovio Pharmaceuticals, she led R&D teams that advanced multiple clinical-stage programmes, including a DNA-based COVID-19 vaccine through Phase 3 testing, and secured over $100 million in non-dilutive funding. The appointment comes as Artis prepares to close its acquisition of Syngoi Technologies, expected in the first quarter of 2026. Dr Broderick holds a PhD in Molecular Genetics from the University of Glasgow.